Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential a

uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate

~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for

~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earn

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business

QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulat

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and c

uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal w

LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a lea

uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reduc

QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing

~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early b

QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-te

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend

uniQure N.V. surges as the FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accel

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

US stocks up, Dow Jones up 171 pts. Replimune Group rises after FDA agreement. Other big gainers inc

Wall Street analysts upgraded Uniqure NV, Apyx Medical Inc, J M Smucker Co, and VTEX with raised pri

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g

Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-r

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty i